MARKET

XENE

XENE

Xenon Pharmaceut
NASDAQ
44.06
+0.40
+0.92%
After Hours: 44.06 0 0.00% 17:56 12/12 EST
OPEN
43.80
PREV CLOSE
43.66
HIGH
44.57
LOW
43.28
VOLUME
821.05K
TURNOVER
--
52 WEEK HIGH
46.60
52 WEEK LOW
26.74
MARKET CAP
3.40B
P/E (TTM)
-11.3422
1D
5D
1M
3M
1Y
5Y
1D
Xenon Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Dow Jones · 3d ago
Xenon Pharmaceuticals Price Target Raised to $48.00/Share From $44.00 by Wells Fargo
Dow Jones · 3d ago
Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $48
Benzinga · 3d ago
Xenon (XENE) Receives a Buy from Wedbush
TipRanks · 3d ago
XENON PHARMACEUTICALS, INC. <XENE.O>: WELLS FARGO RAISES TARGET PRICE TO $48 FROM $44
Reuters · 3d ago
Xenon Pharmaceuticals: Strategic Advancements and Promising Clinical Results Justify Buy Rating
TipRanks · 3d ago
Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares
Reuters · 5d ago
Noteworthy Monday Option Activity: MDB, XENE, SNOW
NASDAQ · 6d ago
More
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Webull offers Xenon Pharmaceuticals Inc stock information, including NASDAQ: XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.